Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Eli Lilly (LLY) and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of ...

“We are delighted with Eli Lilly’s decision to establish ... LCCP also hosts drug development scientists working on global teams developing new medicines for diabetes, cardiovascular disease, dementia ...

New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...

Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...